Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation
Open accessAbstract
Advances in hematopoietic cell transplantation (HCT) technology and supportive care techniques have led to improvements in long-term survival after HCT. Emerging indications for transplantation, introduction of newer graft sources (for example, umbilical cord blood) and transplantation of older patients using less intense conditioning regimens have also contributed to an increase in the number of HCT survivors. These survivors are at risk for developing late complications secondary to pre-, peri- and post-transplant exposures and risk factors. Guidelines for screening and preventive practices for HCT survivors were published in 2006. An international group of transplant experts was convened in 2011 to review contemporary literature and update the recommendations while considering the changing practice of transplantation and international applicability of these guidelines. This report provides the updated recommendations for screening and preventive practices for pediatric and adult survivors of autologous and allogeneic HCT.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
HSCT recipients may develop complications of infection and graft-versus-host disease that can be severe, persistent, and may even cause death.
“HSCT recipients may develop complications of infection and graft-versus-host disease that can be severe, persistent, and may even cause death [4-6]”
From Mindfulness, Experiential Avoidance, and Recovery From Hematopoietic Stem Cell Transplantation. (2019) · cites this paper as [4]
Treatment-related side effects such as fatigue and debility can persist for months or even years after HSCT.
“Treatment-related side effects such as fatigue and debility can persist for months or even years [2-4]”
From Mindfulness, Experiential Avoidance, and Recovery From Hematopoietic Stem Cell Transplantation. (2019) · cites this paper as [4]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 73 · Cited by 248
- Authors
- Majhail, N. S., Rizzo, J. D., Lee, S. J., Aljurf, M., Atsuta, Y., Bonfim, C., Burns, L. J., Chaudhri, N., Davies, S., Okamoto, S., Seber, A., Socie, G., Szer, J., Van Lint, M. T., Wingard, J. R., Tichelli, A., & for the Center for International Blood and Marrow Transplant Research, A. S. F. B. A. M. T.
- Affiliations
- National Marrow Donor Program (US)
- Fred Hutch Cancer Center (US)
- King Faisal Specialist Hospital & Research Centre (SA)
- Nagoya University (JP)
- Universidade Federal do Paraná (BR)
- University of Minnesota (US)
- Cincinnati Children's Hospital Medical Center (US)
- Keio University (JP)
- Support group for adolescents and children with cancer (BR)
- The Royal Melbourne Hospital (AU)
- University of Florida Health (US)
- University Hospital of Basel (CH)
- Corresponding author
- Majhail, N S
- Venue
- Bone Marrow Transplantation
- Published
- 2012-03
- Volume
- 47
- Issue
- 3
- Pages
- 337-341
- ISSN
- 0268-3369 (ISSN-L)
- 1476-5365
- PMC
- PMC3393084
- OpenAlex
- W4241418390
- Semantic Scholar
- c7804b1c1f1693930ec42c45ebf8139ad19bfe58
- Cited by
- 248
- References
- 73
- Citations by year
- 2026: 13 · 2025: 13 · 2024: 17 · 2023: 12 · 2022: 21 · 2021: 30 · 2020: 19 · 2019: 14 · 2018: 11 · 2017: 18 · 2016: 16 · 2015: 20 · 2014: 16 · 2013: 24 · 2012: 4
- FWCI
- 13.65
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Bone Marrow Transplantation (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Heart, Lung, and Blood Institute (U01HL069294)
- National Cancer Institute (U24CA76518, U24CA076518)
- Topics
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Health Sciences › Medicine › Oncology › Cancer survivorship and care
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Childhood Cancer Survivors' Quality of Life
- Keywords
- hematopoietic stem cell transplantation, long-term survivors, late complications, screening guidelines, preventive practices, autologous transplantation, allogeneic transplantation, pediatric transplantation, cord blood transplantation, conditioning regimen, survivorship care
- MeSH terms
- Adult, Female, Fetal Blood, Graft vs Host Disease, Humans, Male, Mass Screening, Middle Aged, Postoperative Complications, Risk, Risk Factors, Time Factors, Transplantation, Autologous, Transplantation, Homologous, Treatment Outcome, Guidelines as Topic, Survivors, Hematopoietic Stem Cell Transplantation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
